drugset / Trial / NCT01626859

A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia

NCT01626859

Phase 2/3 Completed 38 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the pharmacokinetics, safety and efficacy of MP-214 in patients with schizophrenia.

Timeline

Start
2012-05
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 3 mg Oral
Subject Cariprazine Small molecule 6 mg Oral
Subject Cariprazine Small molecule 9 mg Oral

Indications